Compare Coinbase Global, Inc. (COIN) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Coinbase Global, Inc. vs Vertex Pharmaceuticals Incorporated — how do they compare? Coinbase Global, Inc. trades at $175.64 (market cap $47.08B), while Vertex Pharmaceuticals Incorporated trades at $503.25 (market cap $128.16B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 2.7× Coinbase Global, Inc.'s market cap, and Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, Coinbase Global, Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Coinbase Global, Inc. for 78 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| COIN | VRTX | |
|---|---|---|
Market Cap | $47.08B | $128.16B |
Volume | 7,082,928 | 806,603 |
Sector | Financials | Health |
52-Week High | $387.00 | $557.96 |
52-Week Low | $141.09 | $407.37 |
Typical Hold Time | 78 Days | 120 Days |
Enterprise Value | $44.73B | $122.29B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
COIN trades at $178.45, down 3.92% with bearish technical signals. The stock shows mixed fundamentals with strong revenue growth to $7.18B in 2025 but negative net income margin of -15.72% and recent earnings misses. Analyst consensus remains positive with 55% buy ratings and $211.55 price target, while technical indicators show support at $177 and resistance at $180.
Outlook remains cautiously optimistic given analyst support and recent CFTC approval for derivatives expansion, but risks include volatile earnings performance, high valuation multiples, and regulatory uncertainty. The stock's current price near support levels presents potential entry point for long-term investors despite near-term headwinds.
Vertex Pharmaceuticals (VRTX) trades at $503.25, showing modest daily gains of 0.16%. The stock faces bearish technical signals with mixed earnings performance, missing Q4 2025 and Q2 2026 EPS estimates but beating Q1 2026. Strong fundamentals include 86% gross margins and 35% net income margins, with revenue projected to grow from $12B to $12.6B in 2026. Recent positive Phase II data for kidney disease drug inaxaplin highlights pipeline progress.
Outlook remains positive with 84% analyst buy ratings and $573 consensus target offering 14% upside. Key risks include reliance on cystic fibrosis franchise and competitive pressures. Earnings consistency and pipeline execution are critical for sustained growth amid current technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Coinbase Global, Inc.
Coinbase Global, Inc. is a regulated cryptocurrency company that provides customers around the world with a platform for buying, selling, transferring, and storing digital assets. The Company offers a variety of products and services that enable individuals, businesses, and developers to participate in the cryptoeconomy.
Read more on COIN →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
